EXHIBIT 99.1

The Joint Corp. Reports Third Quarter 2020 Financial Results

- Grows Revenue 21%, Compared to Q3 2019 –
- Reports Record Net Income of $1.6 Million, Up 160% Compared to Q3 2019 –
- Posts Record Adjusted EBITDA of $2.6 Million, Up 84% Compared to Q3 2019 -
- Increases Total Clinic Count to 560, Opening 22 Clinics in Q3 2020-
- Sells 30 Franchise Licenses in Q3 2020, Up from 28 in Q3 2019 -

SCOTTSDALE, Ariz., Nov. 05, 2020 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), a national operator, manager and franchisor of chiropractic clinics, reported its financial results for the quarter and nine months ended September 30, 2020.

Financial Highlights: Q3 2020 Compared to Q3 2019

Operating Highlights

“Our strong third quarter performance demonstrates our growth momentum is once again taking hold,” said Peter D. Holt, President and Chief Executive Officer of The Joint Corp. “Chiropractic care is an essential healthcare service, which is the foundation of our business model’s resiliency. Outside of increased sanitization and cleanliness procedures, our core concept has remained unchanged. Throughout the pandemic, our patients have continued to rely on their chiropractic care while our doctors have been there to serve them. We thank our patients for their confidence in us and our doctors and staff for their commitment to improving their quality of life.”   

“Our third quarter revenue, profitability, and franchise license sales improved over the same period a year ago, and even more dramatically when compared to the second quarter of 2020. Our strong license sales have set the stage for increased upcoming franchise clinic openings, which we will augment with new corporate clinics. This increases revenue, scale and brand recognition. Confident in our progress, we are reestablishing 2020 full year guidance and expect both revenue and the bottom line to exceed those from 2019. The lower rate of clinic openings during the second quarter due to the pandemic created pent-up demand that we believe will fuel openings in the fourth quarter of 2020 and into 2021. Therefore, we reassert our goal of opening 1,000 clinics by the end of 2023.”

Financial Results for the Three Months Ended September 30: 2020 Compared to 2019

Revenue was $15.4 million in the third quarter of 2020, compared to $12.7 million in the third quarter of 2019, reflecting a greater number of clinics and continued organic growth.

Cost of revenue was $1.7 million, compared to $1.4 million in the third quarter of 2019. The increase was in line with the total increase in franchise sales and reflects higher regional developer royalties and commissions.

Selling and marketing expenses were $1.8 million, increasing 3%, reflecting the timing of advertising spending. General and administrative expenses were $9.4 million, compared to $8.3 million in the third quarter of 2019, primarily due to an increase in payroll and related expenses to support revenue growth and a greater number of clinics.

Net income was a record for the company at $1.6 million, or $0.11 per diluted share, compared to $617,000, or $0.04 per diluted share, in the third quarter of 2019.

Adjusted EBITDA was also a record for the company at $2.6 million, compared to $1.4 million in the third quarter of 2019. The company defines Adjusted EBITDA, a non-GAAP measure, as EBITDA before acquisition-related expenses, bargain purchase gain, net gain/(loss) on disposition or impairment, and stock-based compensation expenses. The company defines EBITDA as net income/(loss) before net interest, tax expense, depreciation, and amortization expenses.

Financial Results for the Nine Months Ended September 30: 2020 Compared to 2019

Revenue was $41.6 million in the first nine months of 2020, increasing 20% compared to $34.6 million in the same period of 2019. This increase reflects gross sales from a greater number of clinics and increased gross sales at existing franchised and company-owned or managed clinics.

Net income was $2.5 million, or $0.17 per diluted share, compared to $2.0 million, or $0.14 per diluted share, in the first nine months of 2019.

Adjusted EBITDA was $5.4 million, compared to $4.1 million in the first nine months of 2019.

Balance Sheet Liquidity
Unrestricted cash was $18.3 million at September 30, 2020, compared to $8.5 million at December 31, 2019. The increase primarily reflects $6.9 million in cash flow from operating activities, $2.7 million borrowed under the CARES Act U.S. Small Business Administration Payroll Protection Program, and $2.0 million drawn on a revolving line of credit, which was offset by $2.2 million in capital expenditures, during the first nine months of 2020.

Reestablished 2020 Guidance for Financial Results and Clinic Openings
Management provided full year 2020 guidance and expects the following:

Conference Call
The Joint Corp. management will host a conference call at 5 p.m. ET on Thursday, November 5, 2020, to discuss the third quarter 2020 results. To gain immediate access to the call, bypass the operator and avoid the queue, you may preregister by clicking here. Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. Those who prefer to call-in directly may do so approximately 20 minutes prior to the start time by dialing 706-643-5902 or 888-869-1189 and using reference code 5655716. The accompanying slide presentation will be in the IR section of the website under Presentations and in Events. A live webcast of the conference call will also be available on the IR section of the company’s website at https://ir.thejoint.com/events. An audio replay will be available two hours after the conclusion of the call through November 12, 2020. The replay can be accessed by dialing 404-537-3406 or 855-859-2056. The passcode for the replay is 5655716.

Non-GAAP Financial Information
This release includes a presentation of non-GAAP financial measures. System-wide sales include sales at all clinics, whether operated by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information is important in understanding the company’s financial performance, because these sales are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base. Comp sales include the sales from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed.

EBITDA and Adjusted EBITDA are presented because they are important measures used by management to assess financial performance, as management believes they provide a more transparent view of the company’s underlying operating performance and operating trends. Reconciliation of net income/(loss) to EBITDA and Adjusted EBITDA is presented in the table below. The company defines Adjusted EBITDA as EBITDA before acquisition-related expenses, bargain purchase gain, net gain/(loss) on disposition or impairment, and stock-based compensation expenses. The company defines EBITDA as net income/(loss) before net interest, tax expense, depreciation, and amortization expenses.

EBITDA and Adjusted EBITDA do not represent and should not be considered alternatives to net income or cash flows from operations, as determined by accounting principles generally accepted in the United States, or GAAP. While EBITDA and Adjusted EBITDA are used as measures of financial performance and the ability to meet debt service requirements, they are not necessarily comparable to other similarly titled captions of other companies due to potential inconsistencies in the methods of calculation. EBITDA and Adjusted EBITDA should be reviewed in conjunction with the company’s financial statements filed with the SEC.

Forward-Looking Statements
This press release contains statements about future events and expectations that constitute forward-looking statements. Forward-looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our growth plans, taking into account the information currently available to us. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the expectations of future results we express or imply in any forward-looking statements, and you should not place undue reliance on such statements. Factors that could contribute to these differences include, but are not limited to, the continuing impact of the COVID-19 outbreak on the economy and our operations (including temporary clinic closures, shortened business hours and reduced patient demand), our failure to develop or acquire company-owned or managed clinics as rapidly as we intend, our failure to profitably operate company-owned or managed clinics, and the other factors described in “Risk Factors” in our Annual Report on Form 10-K as filed with the SEC for the year ended December 31, 2019, as updated or revised for any material changes described in any subsequently-filed Quarterly Reports on Form 10-Q or other SEC filings. Words such as, "anticipates," "believes," "continues," "estimates," "expects," "goal," "objectives," "intends," "may," "opportunity," "plans," "potential," "near-term," "long-term," "projections," "assumptions," "projects," "guidance," "forecasts," "outlook," "target," "trends," "should," "could," "would," "will," and similar expressions are intended to identify such forward-looking statements. We qualify any forward-looking statements entirely by these cautionary factors. We assume no obligation to update or revise any forward-looking statements for any reason or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.

About The Joint Corp. (NASDAQ: JYNT)
The Joint Corp. (NASDAQ: JYNT) revolutionized access to chiropractic care when it introduced its retail healthcare business model in 2010. Today, the company is making quality care convenient and affordable, while eliminating the need for insurance, for millions of patients seeking pain relief and ongoing wellness. With more than 500 locations nationwide and over 7 million patient visits annually, The Joint is a key leader in the chiropractic industry. Named on Franchise Times “Top 200+ Franchises” and Entrepreneur’s “Franchise 500®” lists, The Joint Chiropractic is an innovative force, where healthcare meets retail. For more information, visit www.thejoint.com. To learn about franchise opportunities, visit www.thejointfranchise.com.

Business Structure
The Joint Corp. is a franchisor of clinics and an operator of clinics in certain states. In Arkansas, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky, Maryland, Michigan, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Washington, West Virginia and Wyoming, The Joint Corp. and its franchisees provide management services to affiliated professional chiropractic practices.

Media Contact: Margie Wojciechowski, The Joint Corp., [email protected]
Investor Contact: Kirsten Chapman, LHA Investor Relations, 415-433-3777, [email protected]

– Financial Tables Follow –

 
THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES
CONDENSED CONSOLIDATED BALANCE SHEETS
    
 September 30, December 31,
 2020 2019
ASSETS(unaudited)  
Current assets:   
Cash and cash equivalents$18,305,526  $8,455,989 
Restricted cash 140,400   185,888 
Accounts receivable, net 1,813,684   2,645,085 
Notes receivable, net 10,326   128,724 
Deferred franchise and regional development costs, current portion 828,842   765,508 
Prepaid expenses and other current assets 921,559   1,122,478 
Total current assets 22,020,337   13,303,672 
Property and equipment, net 8,014,676   6,581,588 
Operating lease right-of-use asset 11,555,086   12,486,672 
Deferred franchise and regional development costs, net of current portion 3,757,799   3,627,225 
Intangible assets, net 2,160,944   3,219,791 
Goodwill 4,150,461   4,150,461 
Deposits and other assets 393,508   336,258 
 $52,052,811  $43,705,667 
    
LIABILITIES AND STOCKHOLDERS' EQUITY    
Current liabilities:   
Accounts payable$1,239,522  $1,525,838 
Accrued expenses 894,122   216,814 
Co-op funds liability 140,400   185,889 
Payroll liabilities 2,584,487   2,844,107 
Operating lease liability, current portion 2,756,838   2,313,109 
Finance lease liability, current portion 69,380   24,253 
Deferred franchise and regional developer fee revenue, current portion 2,813,515   2,740,954 
Deferred revenue from company clinics 3,228,368   3,196,664 
Debt under the Paycheck Protection Program, current portion 1,656,292   - 
Other current liabilities 545,834   518,686 
Total current liabilities 15,928,758   13,566,314 
Operating lease liability, net of current portion 10,798,802   11,901,040 
Finance lease liability, net of current portion 150,524   34,398 
Debt under the Credit Agreement and Paycheck Protection Program, net of current portion 3,071,678   - 
Deferred franchise and regional developer fee revenue, net of current portion 12,581,885   12,366,322 
Deferred tax liability 72,841   89,863 
Other liabilities 27,230   27,230 
Total liabilities 42,631,718   37,985,167 
Commitments and contingencies   
Stockholders' equity:   
Series A preferred stock, $0.001 par value; 50,000 shares authorized, 0 issued and outstanding, as of September 30, 2020 and December 31, 2019 -   - 
Common stock, $0.001 par value; 20,000,000 shares authorized, 14,073,244 shares issued and 14,057,201 shares outstanding as of September 30, 2020 and 13,898,694 shares issued and 13,882,932 outstanding as of December 31, 2019 14,073   13,899 
Additional paid-in capital 40,625,128   39,454,937 
Treasury stock 16,043 shares as of September 30, 2020 and 15,762 shares as of December 31, 2019, at cost (115,303)  (111,041)
Accumulated deficit (31,102,905)  (33,637,395)
Total The Joint Corp. stockholders' equity 9,420,993   5,720,400 
Non-controlling Interest 100   100 
Total equity 9,421,093   5,720,500 
Total liabilities and stockholders' equity$52,052,811  $43,705,667 
    


 
THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES
CONDENSED CONSOLIDATED INCOME STATEMENTS
(unaudited)
        
 Three Months Ended Nine Months Ended
 September 30,  September 30,
 2020 2019 2020 2019
Revenues:       
Revenues from company-owned or managed clinics$8,403,844  $6,829,576  $22,554,946  $18,245,940 
Royalty fees 4,170,692   3,447,270   11,157,575   9,737,616 
Franchise fees 519,131   541,339   1,555,846   1,405,678 
Advertising fund revenue 1,187,666   978,209   3,176,080   2,797,576 
Software fees 688,046   514,350   1,964,968   1,256,711 
Regional developer fees 222,908   210,233   643,974   594,615 
Other revenues 218,266   205,400   591,443   537,596 
Total revenues 15,410,553   12,726,377   41,644,832   34,575,732 
Cost of revenues:       
Franchise and regional developer cost of revenues 1,588,707   1,318,966   4,281,389   3,634,397 
IT cost of revenues 123,539   107,903   284,653   297,561 
Total cost of revenues 1,712,246   1,426,869   4,566,042   3,931,958 
Selling and marketing expenses 1,845,601   1,793,229   5,684,556   5,068,585 
Depreciation and amortization 714,288   538,372   2,061,937   1,308,515 
General and administrative expenses 9,433,062   8,297,680   26,668,420   22,078,244 
Total selling, general and administrative expenses 11,992,951   10,629,281   34,414,913   28,455,344 
Net (gain) loss on disposition or impairment -   29,848   (53,413)  116,775 
Income from operations 1,705,356   640,379   2,717,290   2,071,655 
        
Other (expense) income:       
Bargain purchase gain -   -   -   19,298 
Other expense, net (25,667)  (16,697)  (55,248)  (43,469)
Total other expense (25,667)  (16,697)  (55,248)  (24,171)
        
Income before income tax expense 1,679,689   623,682   2,662,042   2,047,484 
        
Income tax expense 75,730   6,702   127,551   15,597 
        
Net income and comprehensive income$1,603,959  $616,980  $2,534,491  $2,031,887 
        
Less: income attributable to the non-controlling interest$-  $-  $-  $- 
        
Net income attributable to The Joint Corp. stockholders$1,603,959  $616,980  $2,534,491  $2,031,887 
        
Earnings per share:       
Basic earnings per share$0.11  $0.04  $0.18  $0.15 
Diluted earnings per share$0.11  $0.04  $0.17  $0.14 
        
Basic weighted average shares 14,033,535   13,846,045   13,968,635   13,798,593 
Diluted weighted average shares 14,593,107   14,526,538   14,523,329   14,442,203 
        


 
THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES
 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
     
     
  Nine Months Ended
  September 30,
  2020 2019
Net income $2,534,491  $2,031,887 
Adjustments to reconcile net income to net cash   
provided by operating activities  2,670,640   1,852,280 
Changes in operating assets and liabilities  1,702,314   821,041 
Net cash provided by operating activities  6,907,445   4,705,208 
Net cash used in investing activities  (2,225,946)  (5,955,484)
Net cash provided by financing activities  5,122,550   391,317 
Net increase (decrease) in cash $9,804,049  $(858,959)
     


 
THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES
RECONCILIATION FOR GAAP TO NON-GAAP
        
 Three Months Ended Nine Months Ended
 September 30, September 30,
Non-GAAP Financial Data:2020
 2019
 2020
 2019
Net income$1,603,959  $616,980  $2,534,491  $2,031,887 
Net interest 25,668   16,697   55,248   43,469 
Depreciation and amortization expense 714,288   538,372   2,061,937   1,308,515 
Tax expense 75,730   6,702   127,551   15,597 
EBITDA$2,419,645  $1,178,751  $4,779,227  $3,399,468 
Stock compensation expense 212,234   186,020   678,706   536,744 
Acquisition related expenses -   33,091   -   36,241 
Bargain purchase gain -   -   -   (19,298)
Net (gain) loss on disposition or impairment -   29,848   (53,413)  116,775 
Adjusted EBITDA$2,631,879  $1,427,710  $5,404,520  $4,069,930 
        

 

_____________________________________
1 System-wide sales include sales at all clinics, whether operated by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information is important in understanding the company’s financial performance, because these sales are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base. 
2 Comp sales include the sales from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed.